Brain gene therapy delivery system tested in kids with rare disorder

NCT ID NCT04903288

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a special needle (SmartFlow cannula) designed to safely deliver a gene therapy drug (eladocagene exuparvovec) into the brains of 13 children with AADC deficiency, a rare genetic disorder that affects movement and development. The main goals are to check if the procedure is safe and if it raises dopamine levels in the brain. The study includes short-term and long-term follow-up to see if the treatment improves motor skills and other symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AADC DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Chaim Sheba Medical Center

    Ramat Gan, 5262000, Israel

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • Duke University Hospital

    Durham, North Carolina, 27705, United States

  • National Taiwan University Hospital, Department of Pediatrics and Medical Genetics

    Taipei, 10041, Taiwan

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.